SCHEMBL2811173

SCHEMBL2811173

O=C(O)c1ccc2c3c(ccc(C(=O)O)c13)C(=O)NC2=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.58
▸ PARP1 P09874 2/20 0.42
▸ LIG1 P18858 1/20 0.42
▸ TYMS P04818 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ POLB P06746 3/20 0.39
▸ RECQL P46063 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ THRB P10828 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ RGS12 O14924 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ BRCA1 P38398 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21953168 0.89 CYP1A2 (0.45) CYP1A2PARP1LIG1TYMSHSD17B10
SCHEMBL30919324 0.80 TYMS (0.68) CYP1A2PARP1LIG1TYMSHSD17B10
SCHEMBL15709476 0.80 TYMS (0.68) CYP1A2PARP1LIG1TYMSHSD17B10
SCHEMBL6069711 0.79 TYMS (0.54) CYP1A2PARP1LIG1TYMSHSD17B10
SCHEMBL4705419 0.79 CYP1A2 (0.82) CYP1A2TYMSHSD17B10KMT2AMAPT
SCHEMBL29716114 0.79 PARP1 (0.59) CYP1A2PARP1GSK3BKMT2AMAPT
SCHEMBL278438 0.79 PARP1 (0.59) CYP1A2PARP1GSK3BKMT2AMAPT
SCHEMBL8726186 0.77 PARP1 (0.56) CYP1A2PARP1GSK3BKMT2AMAPT
SCHEMBL29417502 0.76 CYP1A2 (1.00) CYP1A2HSD17B10MAPTPOLBCYP3A4
SCHEMBL22122 0.76 CYP1A2 (1.00) CYP1A2HSD17B10MAPTPOLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 — — US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 — — US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 — — US claimed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 — — EP disclosed
CN-116322616-A Hair lightening compositions providing damage protection and sensory benefits and methods of use 欧莱雅 2023-06-23 — — CN disclosed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 — — US disclosed
WO-2022047081-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE HENRY DEREK (US) 2022-03-03 — — WO disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 — — US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 — — US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 — — US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 CYP1A2 3261/4885PARP1 1382/4885LIG1 899/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB CYP1A2 4735/4885PARP1 784/4885LIG1 172/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA CYP1A2 1104/4885PARP1 1688/4885LIG1 471/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA CYP1A2 4124/4885PARP1 2369/4885LIG1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback